Article
Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans.
Aging cell - 1 Jun 2015
Golegaonkar Sandeep, Tabrez Syed S, Pandit Awadhesh, Sethurathinam Shalini, Jagadeeshaprasad Mashanipalya G, Bansode Sneha, Sampathkumar Srinivasa-Gopalan, Kulkarni Mahesh J, Mukhopadhyay Arnab
Abstract excerpt
Advanced glycation end products (AGEs) are formed when glucose reacts nonenzymatically with proteins; these modifications are implicated in aging and pathogenesis of many age-related diseases including type II diabetes, atherosclerosis, and neurodegenerative disorders. Thus, pharmaceutical interventions that can reduce AGEs may delay age-onset diseases and extend lifespan. Using LC-MS(E), we show that rifampicin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
